Cantor Fitzgerald Analysts Boost Earnings Estimates for CMPS

COMPASS Pathways plc (NASDAQ:CMPS) – Investment analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of COMPASS Pathways in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of ($1.91) per share for the year, up from their previous estimate of ($2.00). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03.

Several other equities research analysts have also commented on the company. Canaccord Genuity Group cut their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday. Finally, Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $20.20.

COMPASS Pathways Price Performance

NASDAQ:CMPS opened at $3.95 on Wednesday. COMPASS Pathways has a 12 month low of $2.49 and a 12 month high of $8.54. The stock has a 50 day moving average of $3.35 and a two-hundred day moving average of $3.97. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market cap of $366.75 million, a P/E ratio of -1.80 and a beta of 2.27.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CMPS. Geode Capital Management LLC lifted its holdings in COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after acquiring an additional 25,970 shares during the last quarter. Franklin Resources Inc. lifted its holdings in COMPASS Pathways by 4.4% in the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after acquiring an additional 12,599 shares during the last quarter. Green Alpha Advisors LLC lifted its holdings in COMPASS Pathways by 138.3% in the fourth quarter. Green Alpha Advisors LLC now owns 37,614 shares of the company’s stock valued at $142,000 after acquiring an additional 21,833 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in COMPASS Pathways by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after purchasing an additional 26,787 shares during the period. Finally, Flagship Harbor Advisors LLC purchased a new stake in COMPASS Pathways in the fourth quarter valued at approximately $43,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.